Brought to you by 
Transmedic gets Southeast Asian rights to Pharming Group's Ruconest
30 Mar 2012
Executive Summary
Singapore-based medical device and therapeutics company Transmedic Pte. Ltd. has licensed rights to Pharming Group NV’s (drugs for unmet medical needs) Ruconest (recombinant human C1 inhibitor) in the Southeast Asian countries of Brunei, Indonesia, Malaysia, the Philippines, Singapore, and Thailand. The drug is approved for acute attacks of hereditary angioedema (HAE).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Transmedic gets Southeast Asian rights to Pharming Group's Ruconest
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice